Genprex Inc., a clinical-stage gene therapy company, has announced significant progress in its clinical development program for 2025. The company is currently conducting patient treatment in two lung cancer clinical trials. These trials are part of Genprex's larger focus on developing therapies for cancer and diabetes. The results of these clinical studies have not been presented yet, but the company has outlined key milestones for the second half of 2025 and beyond. Further details are available in a stockholder letter and corporate update issued by Genprex, which is accessible on the company's website.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genprex Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: DA42336) on August 04, 2025, and is solely responsible for the information contained therein.